Citi analyst David Lebowitz reiterated a Buy rating and $178.00 price target on Ascendis Pharma (NASDAQ: ASND).The analyst comments "At ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE